
Tirzepatide SURMOUNT-OSA trial and cardiometabolic subanalysis
April 21, 2026
A Podcast on Tirzepatide SURMOUNT-OSA trial and cardiometabolic subanalysis.
A portion of the ATS SRN 360 high impact articles from the past year.
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity – Presented by Richard J Schwab, MD - Perelman School of Medicine, University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders
• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
Presented by Scott A. Sands, Ph.D - Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts
Moderated by Chana Chin, MD from CHOC Children's/Rady's Children's Health and Bradon Nokes, MD from University of California, San Diego
00:00 — Podcast Introduction & Presentation Overview
00:15 — Tirzepatide for Obstructive Sleep Apnea and Obesity
00:47 — SURMOUNT-OSA Trial Design and Patient Population
01:44 — Primary Endpoints and Secondary Outcome Measures
02:53 — Baseline Demographics and Clinical Characteristics
03:52 — Weight Loss Effects and Sleep Apnea Improvement Results
05:52 — Cardiometabolic Outcomes, Blood Pressure, and Safety Findings
08:40 — Clinical Discussion: Prescribing Tirzepatide in OSA Practice
12:03 — Secondary Analysis of Cardiometabolic Risk Mediation
20:08 — Long-Term Use, Mechanisms of Action, and Audience Q&A
Mais episódios de "ATS Assemblies & Sections"



Não percas um episódio de “ATS Assemblies & Sections” e subscrevê-lo na aplicação GetPodcast.








